Nuvalent Inc (NUVL)

Currency in USD
123.53
-0.05(-0.04%)
Closed·
123.530.00(0.00%)
·
NUVL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
123.51123.67
52 wk Range
71.13123.69
Key Statistics
Prev. Close
123.58
Open
123.57
Day's Range
123.51-123.67
52 wk Range
71.13-123.69
Volume
1.19M
Average Vol. (3m)
2.05M
1-Year Change
56.1102%
Book Value / Share
14.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NUVL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
125.13
Upside
+1.29%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Nuvalent Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

0 Buy
17 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 125.13
(+1.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Bernstein SocGen Group
Hold124.00+0.38%172.00DowngradeJun 24, 2026
Bernstein SocGen Group
Buy172.00+39.24%-MaintainJun 10, 2026
Guggenheim
Hold---DowngradeJun 10, 2026
UBS
Hold124.00+0.38%138.00DowngradeJun 10, 2026
Truist Securities
Hold---DowngradeJun 09, 2026

Nuvalent Inc SWOT Analysis


Precision Medicine
The company's focused strategy targeting genetically defined patient populations aligns with industry trends toward personalized cancer therapies, addressing significant unmet needs in specialized oncology segments
Regulatory Momentum
Discover how Nuvalent's completed rolling NDA submission for ROS1-positive patients and anticipated pivotal data by year-end 2025 create near-term catalysts for potential market authorization
Analyst Outlook
Price targets range from $116 to $189 with strong buy consensus, reflecting confidence in the therapeutic approach despite projected losses of approximately $5.61-$5.75 per share through fiscal years
Clinical Excellence
Neladalkib demonstrates exceptional durability of response in ALK-positive non-small cell lung cancer, exceeding initial expectations and positioning as a competitive differentiator in targeted oncology treatments
Read full SWOT analysis

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-1.39 / -1.35
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NUVL Income Statement

Compare NUVL to Peers and Sector

Metrics to compare
NUVL
Peers
Sector
Relationship
P/E Ratio
−21.7x−5.8x−0.4x
PEG Ratio
0.580.020.00
Price / Book
8.3x3.6x2.6x
Price / LTM Sales
-95.0x3.0x
Upside (Analyst Target)
0.4%101.8%56.2%
Fair Value Upside
Unlock−4.7%8.9%Unlock

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
33.56M42.48%4.15B
Other Institutional Investors
85.68M57.52%10.59B
Public Companies & Retail Investors
0.000.00%0.00
Total
119.24M100.00%14.74B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Deerfield Management Company, L.P.28.71%22,683,7042,803,252
Deerfield Healthcare Innovations Fund, L.P.13.95%11,016,8521,361,463

People Also Watch

69.060
AXTI
-1.54%
168.52
CBRS
-7.54%
153.00
SPCX
-1.00%
268.03
CRDO
-0.36%
138.540
AAOI
-5.74%

FAQ

What Is the Nuvalent (NUVL) Stock Price Today?

The Nuvalent stock price today is 123.53 USD.

What Stock Exchange Does Nuvalent Trade On?

Nuvalent is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Nuvalent?

The stock symbol for Nuvalent is "NUVL."

What Is the Nuvalent Market Cap?

As of today, Nuvalent market cap is 9.76B USD.

What Is Nuvalent's Earnings Per Share (TTM)?

The Nuvalent EPS (TTM) is -6.05.

When Is the Next Nuvalent Earnings Date?

Nuvalent will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is NUVL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Nuvalent Stock Split?

Nuvalent has split 0 times.

How Many Employees Does Nuvalent Have?

Nuvalent has 234 employees.

What is the current trading status of Nuvalent (NUVL)?

As of Jun 26, 2026, Nuvalent (NUVL) is trading at a price of 123.53 USD, with a previous close of 123.58 USD. The stock has fluctuated within a day range of 123.51 USD to 123.67 USD, while its 52-week range spans from 71.13 USD to 123.69 USD.

What Is Nuvalent (NUVL) Price Target According to Analysts?

The average 12-month price target for Nuvalent is 125.13 USD, with a high estimate of 140 USD and a low estimate of 124 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +1.29% Upside potential.

What Is the NUVL Premarket Price?

NUVL's last pre-market stock price is 123.54 USD. The pre-market share volume is 5,000.00, and the stock has decreased by -0.04, or -0.03%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.